© Reuters. FILE PHOTO: Vaccination campaign against COVID-19 in Bierset
LONDON (Reuters) – There is a lot of reassuring evidence that suggests there is no increased risk of blood clots from AstraZeneca (NASDAQ:)’s COVID-19 vaccine, England’s deputy chief medical officer said, adding he expected the European Medicines Agency to agree.
“Behind the scenes, there is a lot of work going on to look at whether there is a signal in relation to what we call venous thrombo-embolic events – clots,” Jonathan Van-Tam said at a news conference on Wednesday.
“And there’s a lot of evidence emerging now that is reassuring that there is no overall excess signal or increased risk. And I expect, without prejudice to their absolute findings, those to be the final conclusions of the EMA and (Britain’s) MHRA in due course.”
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.